Home » Newsletters » BioWorld Science

BioWorld Science

July 5, 2019

View Archived Issues

Viral-MS link comes via bad memories

Gut microbiome affects food allergies

Glucagon alpha-cell proliferation declines with age

Dengue virus protein mutation increases disease severity in mice

Patient enrollment ongoing in phase I study of MBS-301

New phase IIa ELEVATE 1 study investigates RVT-1201 for pulmonary arterial hypertension

Janssen Pharmaceutica presents PRMT5 inhibitors

First patient enrolled in IBT's pivotal phase III study of IBP-9414

NeuroVive announces the initiation of the second part of its ongoing phase Ia/b study of KL-1333

Nosopharm and Evotec partner to advance development of novel antibiotics

Vaccex to initiate clinical development of VX-001

Novel ERB antibiotics show promising activity in MRSA thigh infection models

LSS biallelic pathogenic variants are associated with APMR syndrome

Novel genetic variant in CARD11 as a biomarker of profound combined immunodeficiency

SP-8356, a CD147 inhibitor, is a potential compound for treating atherosclerosis

Aquaporin-1 is a potential therapeutic target in TBI, researchers find

Bristol-Myers Squibb patents TLR7, TLR8 and/or TLR9 antagonists

Janssen Biotech patent describes hSTING agonists

REVOLUTION Medicines identifies PTPN11 inhibitors

Pyramid Biosciences synthesizes NTRK1 inhibitors

Innovate UK grant supports ROP cancer vaccine development

FDA approves Xembify for primary immunodeficiencies

WDFY3 gene variants linked to mild to moderate neurodevelopmental delay and intellectual disability

Lasmiditan for acute treatment of migraine: results from phase III trial

EMA validates clinical development program for AB-8939

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Neutrophils put the brakes on fat loss
BioWorld Science
Fat tissue balances energy by storing lipids during times of abundance and mobilizing them when needed, yet sustained metabolic stress demands mechanisms that...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Peptidream reveals milestone in Alnylam collaboration
BioWorld Science
Peptidream Inc. has announced a preclinical development milestone in its collaboration with Alnylam Pharmaceuticals Inc. under their siRNA conjugate discovery...